GlaxoSmithKline files for European approval of diabetes drug albiglutide
Britain's biggest drugmaker GlaxoSmithKline said on Thursday it had filed for European approval of its new once-weekly diabetes drug albiglutide, as tries to gain a foothold in a crowded market.
GlaxoSmithKline has been looking into claims from an anonymous tipster that its Chinese sales staff bribed doctors to prescribe drugs between 2004 and 2010, including for unauthorized uses.